- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04604015
RoBotic TCD Ultrasound BubbLe Study Compared to Transthoracic Echocardiography for Detection of Right to Left Shunt (BUBL)
December 28, 2023 updated by: NovaSignal Corp.
This study is a multi-center, prospective, single-arm, non-significant risk (NSR) device study in which up to 150 evaluable subjects with suspicion of embolic stroke of undetermined source (ESUS) will be evaluated with NB-IS TCD and standard of care TTE to screen for right to left shunt (RLS) or patent foramen ovale (PFO).
Additionally, up to 150 evaluable subjects will be evaluated with NB-IS TCD and standard of care TEE.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The objectives of the study is to evaluate the shunt detection rate of the NeuralBot Investigational System (NB-IS) TCD relative to standard of care diagnostic techniques (transthoracic echocardiography (TTE), transesophageal echocardiography (TEE), and standard transcranial Doppler ultrasound (TCD) and to assess the safety, accuracy and usability of the NB-IS device.
Study Type
Interventional
Enrollment (Actual)
154
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85013
- Barrow Neurological Institute
-
-
Oregon
-
Portland, Oregon, United States, 97225
- Providence St. Vincent Medical Center
-
Portland, Oregon, United States, 97225
- Providence Brain & Spine Institute
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
- CHI Memorial Hospital
-
Memphis, Tennessee, United States, 38163
- The University of Tennessee Health Science Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Houston Methodist Neurological Institute
-
-
Washington
-
Seattle, Washington, United States, 98122
- Swedish Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria TTE Main Study:
- Subject 18 years of age and older.
- Subject presents with a clinical condition characterized by neurological signs and symptoms that, in the opinion of the investigator, include embolic stroke or transient ischemic attack (TIA) in the differential diagnosis.
- Scheduled for a transthoracic echocardiograph (TTE) study with agitated saline contrast (bubble study) per standard of care within ±30 days of informed consent.
- Subject is able to successfully perform a Valsalva Maneuver (VM).
- Subject or Legally Authorized Representative has the ability to provide informed consent and comply with the protocol.
Exclusion Criteria TTE Main Study:
- Subject has undergone a right to left shunt (RLS) or patent foramen ovale (PFO) closure.
- Female who is pregnant or lactating at time of admission
- Subjects who underwent partial or full craniotomy/craniectomy within the past 6 months.
- Subjects who have a physical limitation preventing TCD headset placement
Inclusion Criteria TEE Sub-Study (after first 150 subjects in Main TTE study enrolled):
- Subject 18 years of age and older.
- Subject presents with a clinical condition characterized by neurological signs and symptoms that, in the opinion of the investigator, include embolic stroke or TIA in the differential diagnosis.
- Scheduled for a transesophageal echocardiograph (TEE) study with agitated saline contrast (bubble study) per standard of care within ±30 days of informed consent.
- Subject is able to successfully perform a Valsalva Maneuver (VM).
- Subject or Legally Authorized Representative has the ability to provide informed consent and comply with the protocol.
Exclusion Criteria TEE Sub-Study (after first 150 subjects in Main TTE study enrolled):
- Subject has undergone a right to left shunt (RLS) or patent foramen ovale (PFO) closure.
- Female who is pregnant or lactating at time of admission
- Subjects who underwent partial or full craniotomy/craniectomy within the past 6 months.
- Subjects who have a physical limitation preventing TCD headset placement.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NeuralBot Investigational System/TTE Std of Care
Investigational Robotic Transcranial Doppler (TCD)/TTE Std of Care
|
The NeuralBot Investigational System when used with the Lucid M1 System is a medical ultrasound device which assists the user in the setup and acquisition of cerebral blood flow velocity via the patient's temporal windows.
It is intended for use as an adjunct to standard clinical practices for measuring and displaying cerebral blood flow velocity and the occurrence of transient emboli within the blood stream.
Other Names:
A test that uses ultrasound to create a hemodynamic assessment for major cardiovascular events.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Detection of Right to Left Shunt (RLS)/Patent Foramen Ovale (PFO) Using Robotic Assisted TCD (Study Device)
Time Frame: 1 day
|
The primary outcome measure was the percent detection of Right to Left Shunt using the robotic assisted TCD (study device) and compare it to the percent detection of Right to Left Shunt using standard of care Transthoracic Echocardiography (TTE) for the same patient cohort.
The detection of the Right to Left Shunt included site and independent Core Lab assessment of TTE.
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent detection of RLS/PFO compared to SOC Transcranial Doppler Ultrasound
Time Frame: 1 to 60 days after subject receives robotic transcranial Doppler ultrasound bubble exam
|
Robotic TCD sensitivity greater than or equal to 90% compared to SOC TCD bubble exams
|
1 to 60 days after subject receives robotic transcranial Doppler ultrasound bubble exam
|
Percent detection of RLS/PFO compared to SOC Transesophageal Echocardiography
Time Frame: 1 to 60 days after subject receives robotic transcranial Doppler ultrasound bubble exam
|
Percent detection of RLS/PFO compared to SOC Transesophageal Echocardiography
|
1 to 60 days after subject receives robotic transcranial Doppler ultrasound bubble exam
|
Percent agreement for detection of clinically significant shunts with robotic TCD vs TTE
Time Frame: 1 to 60 days after subject receives robotic transcranial Doppler ultrasound bubble exam
|
Percent agreement for detection of clinically significant shunts with robotic TCD vs TTE
|
1 to 60 days after subject receives robotic transcranial Doppler ultrasound bubble exam
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Andrei Alexandrov, MD, The University of Tennessee Health Science Center
- Principal Investigator: Mark Rubin, MD, The University of Tennessee Health Science Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 6, 2020
Primary Completion (Actual)
October 20, 2021
Study Completion (Actual)
November 2, 2021
Study Registration Dates
First Submitted
October 22, 2020
First Submitted That Met QC Criteria
October 25, 2020
First Posted (Actual)
October 27, 2020
Study Record Updates
Last Update Posted (Estimated)
January 24, 2024
Last Update Submitted That Met QC Criteria
December 28, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Congenital Abnormalities
- Brain Ischemia
- Stroke
- Heart Defects, Congenital
- Cardiovascular Abnormalities
- Heart Septal Defects, Atrial
- Heart Septal Defects
- Ischemic Stroke
- Ischemic Attack, Transient
- Foramen Ovale, Patent
- Embolic Stroke
Other Study ID Numbers
- NA-07BBL-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Transient Ischemic Attack
-
Lawson Health Research InstituteHeart and Stroke Foundation of OntarioCompleted
-
University of California, San DiegoWithdrawnStroke | Transient Ischemic Attack (TIA)United States
-
Hamad Medical CorporationUnknownStroke | Transient Ischemic Attack (TIA)Qatar
-
Versailles HospitalCompletedCryptogenic Transient Ischemic Attack and Minor StrokeFrance
-
University of NottinghamNottingham University Hospitals NHS Trust; The Stroke Association, United KingdomCompletedStroke | Transient Ischaemic AttackUnited Kingdom
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
Uppsala County Council, SwedenUnknownAcute Stroke | TIA (Transient Ischemic Attack)Sweden
-
AstraZenecaCompletedAcute Ischaemic Stroke | Transient Ischaemic AttackBelgium, France, Italy, Spain, Sweden, Thailand, Germany, Korea, Republic of, Brazil, Hungary, India, Mexico, Vietnam, China, Taiwan, Hong Kong, Slovakia, Australia, Poland, Saudi Arabia, Ukraine, Canada, Russian Federation, Bulgaria, R... and more
-
University of AlbertaHeart and Stroke Foundation of Canada; Alberta Heritage Foundation for Medical...CompletedIschemic Stroke | Transient Ischemic AttacksCanada
-
NHS Greater Glasgow and ClydeUniversity of GlasgowUnknownStroke | Transient Ischaemic Attack
Clinical Trials on NeuralBot Investigational System
-
Ascensia Diabetes CareCompleted
-
HistoSonics, Inc.RecruitingKidney Cancer | Kidney Neoplasms | Renal Cancer | Tumor | Tumor, Solid | Tumor, BenignUnited Kingdom
-
Seattle Institute for Cardiac ResearchCardiac Science Corporation.CompletedAtrial Fibrillation | Syncope | Supraventricular Tachycardia | Pre-syncopeUnited States, New Zealand
-
Ascensia Diabetes CareCompleted
-
Johnson & Johnson Consumer Inc. (J&JCI)Completed
-
SeqirusCompletedInfluenzaAustralia, New Zealand, Philippines, South Africa
-
Ecole Polytechnique Fédérale de LausanneRecruitingSpinal Cord InjuriesSwitzerland
-
Ascensia Diabetes CareCompleted
-
Ascensia Diabetes CareCompletedDiabetesUnited States